HAHidetaka Akita

Hidetaka Akita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hidetaka Akita has a total of 342 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroki Tanaka

    Tohoku University 6-3, Aoba, Aramaki, Aoba-ku

    25 shared publications
  • Kota Tange

    Life Science Research Laboratory, NOF Corporation, 3-3 Chidori-cho, Kawasaki-ku, Kawasaki city, Kanagawa 210-0865, Japan

    23 shared publications
  • Yuta Nakai

    NOF CORPORATION 3-3 Chidori-cho, Kawasaki-ku

    22 shared publications
  • Hideyoshi Harashima

    Laboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12 Nishi-6, Kita-ku, Sapporo 060-0812, Japan

    21 shared publications
  • Hiroki Tanaka

    Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai city, Miyagi 980-8578, Japan

    21 shared publications
  • Hideyoshi Harashima

    Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo, Hokkaido, Japan

    16 shared publications

Latest Publications

  • Open Access

    Preparation of Antibody-Modified mRNA-LNPs via a Combination of Post-Encapsulation and Post-Insertion

    by Yoshie Ri, Shion Oshima, Hiroki Tanaka, Takumi Sugawara, Mizuho Hori, Siril Yves Junior, Yuta Nakai, Kasumi Ito, Kazuto Shimoya, Yu Sakurai, et al.

    Using ligand-modified lipid nanoparticles (LNPs) to encapsulate messenger RNA (mRNA) has become an important modality for tissue/organ/cell-specific gene delivery. Modifying mRNA-LNPs either with antibodies or their derivatives (Ab-mRNA-LNPs) has emerged as a promising drug delivery system (DDS) due to its efficacy and target specificity. Manufacturing Ab-mRNA-LNPs, however, involves complex and multi-step procedures that include the encapsulation of mRNA followed by the anchoring of antibodies via polyethylene glycol (PEG) linker-conjugated lipids. In this work, we present a seamless strategy for the production of Ab-mRNA-LNPs by integrating the post-encapsulation of mRNA into mRNA-free LNPs (fLNPs) with a post-insertion of ligand-conjugated PEG-lipid (Lig-PEG-lipid). Using a T-cell-targeting model, we further describe how targeting efficacy is influenced by controlling the surface nature of the Ab-mRNA-LNPs either via the modification of PEG-lipids or by replacing the phospholipids. Modification of the DSPE-PEG-methoxy and employment of either DSPC or DPPC significantly improves the accumulation of Ab-mRNA-LNPs in T cells. These findings highlight the importance of LNP surface engineering.

  • Open Access

    Combining Anti-Inflammatory Drugs and Cell-Specific Expression-Suppression Reduces the Adjuvant Activity of mRNA-LNPs

    by Hiroki Tanaka, Naomasa Nishiumi, Daiki Shirane, Yuto Kosegawa, Yves Junior Siril, Hidetaka Akita

    Lipid nanoparticles (LNPs)-encapsulating mRNA (mRNA-LNPs) have become an important modality for vaccine development. mRNA-LNPs also have the ability to introduce therapeutic proteins, which suggests that they should also be a promising modality for gene therapy. However, the intrinsic adjuvant activity of mRNA-LNPs is a fundamental function of the LNPs in RNA vaccines, and this has shown a potential risk of inducing anti-transgene immunity when mRNA-LNPs were used in gene therapy. Therefore, a reduction in the adjuvant activity and adaptive immunity against an expressed protein are prerequisites for therapeutic applications. In this study, two strategies were combined to modulate the adjuvant activity of subcutaneously injected mRNA-LNPs: (1) loading a lipid derivative of dexamethasone to suppress inflammation and (2) inserting a sequence complementary to microRNA-142 into the mRNA to suppress gene expression in immune cells. The combination of these strategies reduced immune reactions against the model antigen ovalbumin in mRNA-LNPs.

  • Open Access

    Combination of ionizable lipids with oleic acid and vitamin E scaffolds for RNA cancer vaccine delivery

    by Jessica Anindita, Hiroki Tanaka, Ryotaro Oyama, Atsuya Matsumaru, Yuta Nakai, Kota Tange, Koji Nagaoka, Hideyuki Nakanishi, Takeshi Kawamura, Toshiya Tanaka, et al.


  • Open Access

    Modulating Immunogenicity and Reactogenicity in mRNA-Lipid Nanoparticle Vaccines through Lipid Component Optimization

    by Yoshino Kawaguchi, Mari Kimura, Tatsuya Karaki, Hiroki Tanaka, Chikako Ono, Tatsuhiro Ishida, Yoshiharu Matsuura, Toshiro Hirai, Hidetaka Akita, Taro Shimizu, et al.

    Messenger RNA (mRNA) vaccines effectively induce antibody production and T cell responses. However, adverse reactions, such as fatigue and fever, following administration remain a key challenge. To modulate the immunogenicity and reactogenicity of mRNA vaccines, the optimization of lipid nanoparticle (LNP) formulations has been attempted, particularly by screening ionizable lipids. In contrast, the potential impact of modifying other LNP components─poly(ethylene glycol) (PEG)-lipids, cholesterol, and phospholipids─on overall vaccine effects and adverse reactions remains underexplored. Here, we prepared mRNA-LNP formulations with altered structures and molar ratios of these components to assess their effects on in vivo protein expression, as well as on the induction of antigen-specific immune responses and adverse reactions. Reducing the PEG chain length and molar ratio of PEG-lipids increased antigen-specific antibody and CD8+ T cell responses. LNPs with cholesterol substituted by plant sterols, or LNPs with phospholipids replaced by those with different head and tail group structures, induced antigen-specific antibody and CD8+ T cell responses comparable to the control formulation. Alternately, these LNPs significantly reduced inflammatory cytokine production and adverse reactions, including fever, compared with the control LNPs. Finally, correlation analysis revealed a positive association between protein expression in specific organs and the magnitude of immune responses and adverse reactions. These findings demonstrate that modifying PEG-lipids, cholesterol, and phospholipids is beneficial for modulating the immunogenicity and reactogenicity of the mRNA-LNP vaccine.


  • Open Access

    A Post-Encapsulation Method for the Preparation of mRNA-LNPs via the Nucleic Acid-Bridged Fusion of mRNA-Free LNPs

    by Hiroki Tanaka, Yuka Sato, Tomoya Nakabayashi, Akari Tanaka, Kazuma Nishio, Chika Matsumoto, Atsuya Matsumaru, Takuma Yamakawa, Kota Ishizaki, Keisuke Ueda, et al.

    Lipid nanoparticles with encapsulated mRNA (mRNA-LNPs) have become key modalities for personalized medicines and RNA vaccines. Once the platform technology is established, the mRNA-LNPs could be applicable to a variety of protein-based therapeutic strategies. A post-encapsulation method, in which the mRNA solution is incubated with preformed mRNA-free LNPs to prepare the mRNA-LNPs, would accelerate the development of RNA-based therapeutics since even nonexperts could manufacture the mRNA-LNPs. In this study, we describe that the post-encapsulation of mRNA into mRNA-free LNPs is accompanied by "nucleic acid-bridged fusion" of them. The adsorption of mRNA onto mRNA-free LNPs via electrostatic interactions and the internalization of mRNA into the LNPs via particle-to-particle fusion are two steps that occur at different levels of pH. To complete post-encapsulation using only one-step mixing, the pH must be controlled within a limited region where both processes occur simultaneously. The size of the mRNA-free LNPs determines the effectiveness of mRNA loading.


  • Open Access

    Control of the Particle Trafficking and Dynamics of the Lymphatic System and of the Cellular Microenvironment

    by Hiroki Tanaka, Hidetaka Akita

    The lymphatic system is a vascular system that runs throughout the body as a second-tier bodily fluid transport system alongside the blood circulatory system. Peripheral lymphatic vessels originate from the subcutaneous tissue and connect to lymph nodes.


  • Intracellular Environment–responsive Lipids for RNA Drug Discovery: Design and Function

    by Hidetaka Akita

    The concept of “precision medicine”, which analyzes genomic information at the individual patient level and utilizes it for treatment, is rapidly expanding. Gene therapy and nucleic acid therapy, which complement and suppress the expression of disease–related genes respectively, are expected to become powerful technologies to meet unmet medical needs. Notably, an RNA vaccine against SARS–CoV–2 has been approved. This historical success now accelerates the innovation of mRNA–based medicine worldwide. In these application, lipid nanoparticles (LNPs) are the key delivery system of mRNA and nucleic acids. In this manuscript, the basic concept and design of the intracellular environment–responsive lipid will be summarized. In parallel, I will introduce our original lipid–like materials (ssPalm: SS–cleavable and pH–activated lipid–like material), and application using these materials.

  • Open Access

    Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles

    by Daiki Omata, Eigo Kawahara, Lisa Munakata, Hiroki Tanaka, Hidetaka Akita, Yasuo Yoshioka, Ryo Suzuki

    Lipid nanoparticle-encapsulated mRNA (mRNA-LNP) vaccines have been approved for use to combat coronavirus disease 2019 (COVID-19). The mRNA-LNPs contain PEG-conjugated lipids. Clinical studies have reported that mRNA-LNPs induce the production of anti-PEG antibodies, but the anti-PEG antibodies do not affect the production of neutralizing antibodies. However, the detailed influence of anti-PEG antibodies on mRNA-LNP vaccines remains unclear. Therefore, in this study, we prepared ovalbumin (OVA) as a model antigen-encoding mRNA-loaded LNP (mRNA-OVA-LNP), and we determined whether anti-PEG antibodies could affect the antigen-specific immune response of mRNA-OVA-LNP vaccination in mice pretreated with PEG-modified liposomes to induce the production of anti-PEG antibodies. After intramuscular (i.m.) injection of the mRNA-LNP, the anti-PEG antibodies did not change the expression of protein or induction of cytokine and cellular immune response but did slightly increase the induction of antigen-specific antibodies. Furthermore, repeated mRNA-LNP i.m. injection induced the production of anti-PEG IgM and anti-PEG IgG. Our results suggest that mRNA-LNP induces the production of anti-PEG antibodies, but the priming of the antigen-specific immune response of mRNA-LNP vaccination is not notably affected by anti-PEG antibodies.


  • Open Access

    The stress-responsive cytotoxic effect of diesel exhaust particles on lymphatic endothelial cells

    by Yu Sakurai, Eiki Oba, Akiko Honda, Hiroki Tanaka, Hirohisa Takano, Hidetaka Akita

    Diesel exhaust particles (DEPs) are very small (typically < 0.2 μm) fragments that have become major air pollutants. DEPs are comprised of a carbonaceous core surrounded by organic compounds such as polycyclic aromatic hydrocarbons (PAHs) and nitro-PAHs. Inhaled DEPs reach the deepest sites in the respiratory system where they could induce respiratory/cardiovascular dysfunction. Additionally, a previous study has revealed that a portion of inhaled DEPs often activate immune cells and subsequently induce somatic inflammation. Moreover, DEPs are known to localize in lymph nodes. Therefore, in this study we explored the effect of DEPs on the lymphatic endothelial cells (LECs) that are a constituent of the walls of lymph nodes. DEP exposure induced cell death in a reactive oxygen species (ROS)-dependent manner. Following exposure to DEPs, next-generation sequence (NGS) analysis identified an upregulation of the integrated stress response (ISR) pathway and cell death cascades. Both the soluble and insoluble components of DEPs generated intracellular ROS. Three-dimensional Raman imaging revealed that DEPs are taken up by LECs, which suggests internalized DEP cores produce ROS, as well as soluble DEP components. However, significant cell death pathways such as apoptosis, necroptosis, ferroptosis, pyroptosis, and parthanatos seem unlikely to be involved in DEP-induced cell death in LECs. This study clarifies how DEPs invading the body might affect the lymphatic system through the induction of cell death in LECs.


  • Open Access

    Lymphatic Endothelial Cells Produce Chemokines in Response to the Lipid Nanoparticles Used in RNA Vaccines

    by Yi Liu, Miho Suzuoki, Hiroki Tanaka, Yu Sakurai, Hiroto Hatakeyama, Hidetaka Akita

    RNA vaccines based on Lipid nanoparticles (LNP) were put into practical use within only one year after the global outbreak of the coronavirus disease 2019 (COVID-19). This success of RNA vaccine highlights the utility of an mRNA delivery system as a vaccination strategy. Potent immunostimulatory activity of LNPs (i.e., inflammation occurring at the injection site and the production of inflammatory cytokines) have recently been reported. However, we have only limited knowledge concerning which cells are responsible for responding to the LNPs. We report herein on in vitro chemokine production from non-immune cells in response to exposure to LNPs. In this study, SM-102, an ionizable lipid that is used in the approved RNA vaccine for the clinical usage of COVID-19 mRNA vaccine, was used. Immortalized mouse lymphatic endothelial cells (mLECs) or professional antigen presenting cells (APCs) such as RAW 264.7 monocyte/macrophage cells were incubated with LNPs that contained no mRNA. As a result, chemokines involved in the recruitment of monocytes/neutrophils were produced only by the mLECs following the LNP treatment. These findings indicate that LEC appear to serve as the cell that sends out initial signals to response LNPs.